CLAYTON QUINN: Open Payments
NPI 1497006183 · WILMINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$439 in 22 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $233 · 2025 $439
Food & beverage: $439
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $65 |
| Teva Pharmaceuticals USA, Inc. | 3 | $61 |
| E.R. Squibb & Sons, L.L.C. | 3 | $60 |
| Indivior Inc. | 3 | $57 |
| Neurocrine BioSciences, Inc. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Braeburn Inc. | 1 | $22 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
| ABBVIE INC. | 1 | $16 |
Products named: CAPLYTA, COBENFY, SUBLOCADE, INGREZZA, HETLIOZ, AUSTEDO XR, UZEDY, REXULTI.
Industry payments across NC — which companies pay providers there.
